BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Katsiki N, Dimitriadis G, Hahalis G, Papanas N, Tentolouris N, Triposkiadis F, Tsimihodimos V, Tsioufis C, Mikhailidis DP, Mantzoros C. Sodium-glucose co-transporter-2 inhibitors (SGLT2i) use and risk of amputation: an expert panel overview of the evidence. Metabolism. 2019;96:92-100. [PMID: 30980838 DOI: 10.1016/j.metabol.2019.04.008] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 8.7] [Reference Citation Analysis]
Number Citing Articles
1 Kalra S, Shetty KK, Nagarajan VB, Ved JK. Basic and Clinical Pharmaco-Therapeutics of SGLT2 Inhibitors: A Contemporary Update. Diabetes Ther 2020;11:813-33. [PMID: 32130664 DOI: 10.1007/s13300-020-00789-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
2 Katsiki N, Mikhailidis DP. Management of patients with type 2 diabetes mellitus and acute coronary syndrome: Better be safe than sorry! Journal of Diabetes and its Complications 2019;33:465-7. [DOI: 10.1016/j.jdiacomp.2019.04.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
3 Katsiki N, Ferrannini E, Mantzoros C. New American Diabetes Association (ADA)/European Association for the Study of Diabetes (EASD) guidelines for the pharmacotherapy of type 2 diabetes: Placing them into a practicing physician's perspective. Metabolism 2020;107:154218. [DOI: 10.1016/j.metabol.2020.154218] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
4 Vlachopoulos C, Terentes-Printzios D, Tsioufis K. Do SGLT2 inhibitors increase the risk of amputation? Make haste slowly. Eur Heart J 2021;42:1739-41. [PMID: 33374009 DOI: 10.1093/eurheartj/ehaa1022] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
5 Muzurović E, Dragnić S, Medenica S, Smolović B, Bulajić P, Mikhailidis DP. Weight-centric pharmacological management of type 2 diabetes mellitus – An essential component of cardiovascular disease prevention. Journal of Diabetes and its Complications 2020;34:107619. [DOI: 10.1016/j.jdiacomp.2020.107619] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
6 Katsiki N, Kotsa K, Stoian AP, Mikhailidis DP. Hypoglycaemia and Cardiovascular Disease Risk in Patients with Diabetes. Curr Pharm Des 2020;26:5637-49. [PMID: 32912117 DOI: 10.2174/1381612826666200909142658] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Koufakis T, Papanas N, Dimitriadis G, Zebekakis P, Kotsa K. Interpreting the results of the VERTIS-CV trial: Is this the end of the "class effect" perspective? J Diabetes 2020;12:942-5. [PMID: 32886864 DOI: 10.1111/1753-0407.13105] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
8 Gupta R, Alcantara R, Popli T, Mahajan S, Tariq U, Dusaj RS, Malik AH. Myopathy Associated With Statins and SGLT2 - A Review of Literature. Curr Probl Cardiol 2021;46:100765. [PMID: 33385749 DOI: 10.1016/j.cpcardiol.2020.100765] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Javed S, Hayat T, Menon L, Alam U, Malik RA. Diabetic peripheral neuropathy in people with type 2 diabetes: too little too late. Diabet Med 2020;37:573-9. [PMID: 31797434 DOI: 10.1111/dme.14194] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
10 Montada-Atin T, Prasad GVR. Recent advances in new-onset diabetes mellitus after kidney transplantation. World J Diabetes 2021; 12(5): 541-555 [PMID: 33995843 DOI: 10.4239/wjd.v12.i5.541] [Reference Citation Analysis]
11 Genuardi MV, Mather PJ. The dawn of the four-drug era? SGLT2 inhibition in heart failure with reduced ejection fraction. Ther Adv Cardiovasc Dis 2021;15:17539447211002678. [PMID: 33779401 DOI: 10.1177/17539447211002678] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Giorgino F, Caruso I, Moellmann J, Lehrke M. Differential indication for SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with established atherosclerotic heart disease or at risk for congestive heart failure. Metabolism 2020;104:154045. [PMID: 31821814 DOI: 10.1016/j.metabol.2019.154045] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
13 Muzurović EM, Mikhailidis DP. Diabetes Mellitus and Noncardiac Atherosclerotic Vascular Disease-Pathogenesis and Pharmacological Treatment Options. J Cardiovasc Pharmacol Ther 2021;26:25-39. [PMID: 32666812 DOI: 10.1177/1074248420941675] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
14 Elkazzaz SK, Khodeer DM, El Fayoumi HM, Moustafa YM. Role of sodium glucose cotransporter type 2 inhibitors dapagliflozin on diabetic nephropathy in rats; Inflammation, angiogenesis and apoptosis. Life Sci 2021;280:119018. [PMID: 33549594 DOI: 10.1016/j.lfs.2021.119018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
15 Yang L, Gabriel N, Hernandez I, Winterstein AG, Guo J. Using machine learning to identify diabetes patients with canagliflozin prescriptions at high-risk of lower extremity amputation using real-world data. Pharmacoepidemiol Drug Saf 2021;30:644-51. [PMID: 33606340 DOI: 10.1002/pds.5206] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Zelniker TA, Braunwald E. Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review. J Am Coll Cardiol 2020;75:435-47. [PMID: 32000956 DOI: 10.1016/j.jacc.2019.11.036] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 15.0] [Reference Citation Analysis]
17 Ravindran S, Munusamy S. Renoprotective mechanisms of sodium-glucose co-transporter 2 (SGLT2) inhibitors against the progression of diabetic kidney disease. J Cell Physiol 2021. [PMID: 34713897 DOI: 10.1002/jcp.30621] [Reference Citation Analysis]
18 Katsiki N, Perakakis N, Mantzoros C. Effects of sodium-glucose co-transporter-2 (SGLT2) inhibitors on non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Ex quo et quo vadimus? Metabolism 2019;98:iii-ix. [PMID: 31301336 DOI: 10.1016/j.metabol.2019.07.009] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
19 Papadimitriou L, Hernandez GA, Lennep B, Long RC, Butler J, Kalogeropoulos AP. Novel Therapies in Heart Failure with Reduced Ejection Fraction: from Soluble Guanylyl Cyclase Stimulators to Cardiac Myosin Activators. Curr Treat Options Cardio Med 2021;23. [DOI: 10.1007/s11936-021-00905-6] [Reference Citation Analysis]
20 Katsiki N, Kotsa K, Kotsis V. Empagliflozin effects on cardiac remodeling: re-shaping the future of heart failure prevention. Expert Rev Cardiovasc Ther 2020;18:841-2. [PMID: 32897742 DOI: 10.1080/14779072.2020.1822069] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
21 Katsiki N, Mikhailidis DP. Iron absorption, bone marrow fat and hematopoiesis in heart failure: Additional mechanisms of action for sodium-glucose co-transporter 2 inhibitors (SGLT2i)? Journal of Diabetes and its Complications 2019;33:107408. [DOI: 10.1016/j.jdiacomp.2019.07.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
22 Kameda T, Kumamaru H, Nishimura S, Kohsaka S, Miyata H. Use of oral antidiabetic drugs in Japanese working-age patients with type 2 diabetes mellitus: dosing pattern for metformin initiators. Curr Med Res Opin 2020;36:749-56. [PMID: 32050809 DOI: 10.1080/03007995.2020.1729710] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
23 Tentolouris A, Vlachakis P, Tzeravini E, Eleftheriadou I, Tentolouris N. SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects. Int J Environ Res Public Health 2019;16:E2965. [PMID: 31426529 DOI: 10.3390/ijerph16162965] [Cited by in Crossref: 46] [Cited by in F6Publishing: 35] [Article Influence: 15.3] [Reference Citation Analysis]
24 Koufakis T, Mustafa OG, Ajjan RA, Garcia-Moll X, Zebekakis P, Dimitriadis G, Kotsa K. The use of sodium-glucose co-transporter 2 inhibitors in the inpatient setting: Is the risk worth taking? J Clin Pharm Ther 2020;45:883-91. [PMID: 31905245 DOI: 10.1111/jcpt.13107] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
25 Papadokostaki E, Rizos E, Tigas S, Liberopoulos EN. Canagliflozin and Amputation Risk: Evidence So Far. The International Journal of Lower Extremity Wounds 2020;19:21-6. [DOI: 10.1177/1534734619878090] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
26 Katsiki N, Banach M, Mikhailidis DP. Is type 2 diabetes mellitus a coronary heart disease equivalent or not? Do not just enjoy the debate and forget the patient! Arch Med Sci 2019;15:1357-64. [PMID: 31749862 DOI: 10.5114/aoms.2019.89449] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
27 Papakitsou I, Vougiouklakis G, Elisaf MS, Filippatos TD. Differential pharmacology and clinical utility of dapagliflozin in type 2 diabetes. Clin Pharmacol 2019;11:133-43. [PMID: 31572020 DOI: 10.2147/CPAA.S172353] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
28 Heyward J, Mansour O, Olson L, Singh S, Alexander GC. Association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and lower extremity amputation: A systematic review and meta-analysis. PLoS One 2020;15:e0234065. [PMID: 32502190 DOI: 10.1371/journal.pone.0234065] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 9.0] [Reference Citation Analysis]
29 Anastasilakis AD, Sternthal E, Mantzoros CS. Beyond glycemic control: New guidance on cardio-renal protection. Metabolism 2019;99:113-5. [PMID: 30797784 DOI: 10.1016/j.metabol.2019.02.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
30 Alshnbari A, Alkharaiji M, Anyanwagu U, Idris I. Diuretics and risk of lower extremity amputation amongst patients with insulin-treated type 2 diabetes - exploring the mechanism of possible sodium glucose co-transporter 2 inhibitor induced risk of lower extremity amputations. Curr Med Res Opin 2020;36:1985-9. [PMID: 33085525 DOI: 10.1080/03007995.2020.1840340] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]